Citations

Clear

163 citation(s) found for "Sharp, H L".

Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop
Bilezikian, John P. , Khan, Aliya , Silverberg, Shonni J. , Fuleihan, Ghada El‐Hajj , Marcocci, Claudio , Minisola, Salvatore , Perrier, Nancy D. , Sitges‐Serra, Antonio , Thakker, Rajesh V. , Guyatt, Gordon , Mannstadt, Michael , Potts, John T. , Hyperparathyroidism, On behalf of the International Workshop on Primary, Khan, Aliya A , Perrier, Nancy , Clarke, Bart L , Brandi, Maria Luisa , El-Hajj Fuleihan, Ghada , Thakker, Rajesh V , Mannstadt, Michael , Guyatt, Gordon , Clarke, B.L. , Brandi, Maria Luisa , Hyperparathyroidism, On behalf of the International Workshop on Primary

Mayo Clinic

Journal of Bone and Mineral Research | August 19, 2022 | Volume: 37 | Issue: 11 | Pages: 2293-2314

10.1002/jbmr.4677 | PMID 36245251 Get It

ABSTRACT The last international guidelines on the evaluation and management of primary hyperparathyroidism (PHPT) were published in 2014. Research since that time has led to new insights into epidemiology, pathophysiology, diagnosis, measurements, genetics, outcomes, presentations, new imaging modalities, target and other organ systems, pregnancy, evaluation, and management. Advances in all these areas are demonstrated by the reference list in which the majority of listings were published after the last set of guidelines. It was thus, timely to convene an international group of over 50 experts to review these advances in our knowledge. Four Task Forces considered: 1. Epidemiology, Pathophysiology, and Genetics; 2. Classical and Nonclassical Features; 3. Surgical Aspects; and 4. Management. For Task Force 4 on the Management of PHPT, Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) methodology addressed surgical management of asymptomatic PHPT and non-surgical medical management of PHPT. The findings of this systematic review that applied GRADE methods to randomized trials are published as part of this series. Task Force 4 also reviewed a much larger body of new knowledge from observations studies that did not specifically fit the criteria of GRADE methodology. The full reports of these 4 Task Forces immediately follow this summary statement. Distilling the essence of all deliberations of all Task Force reports and Methodological reviews, we offer, in this summary statement, evidence-based recommendations and guidelines for the evaluation and management of PHPT. Different from the conclusions of the last workshop, these deliberations have led to revisions of renal guidelines and more evidence for the other recommendations. The accompanying papers present an in-depth discussion of topics summarized in this report. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG)
Monahan, Kevin , Davies, Michael , Abulafi, Muti , Banerjea, Ayan , Nicholson, Brian D , Arasaradnam, Ramesh , Barker, Neil, Booth, Richard F. , Burling, David , Carten, Rachel , Kleijnen, Jos , Machesney, Michael , Pettman, Maria, Pipe, Jenny, Saker, L., Sharp, Linda , Stephenson, James A. , Steele, R. , Monahan, Kevin J , D'Souza, Nigel , East, James E , Sharp, Linda , Steele, Robert Jc , Benton, Sally C. , Booth, Richard, East, James E.

Mayo Clinic

Gut | July 12, 2022 | Volume: 71 | Issue: 10 | Pages: 1939-1962

10.1136/gutjnl-2022-327985 | PMID 35820780 Get It

Faecal immunochemical testing (FIT) has a high sensitivity for the detection of colorectal cancer (CRC). In a symptomatic population FIT may identify those patients who require colorectal investigation with the highest priority. FIT offers considerable advantages over the use of symptoms alone, as an objective measure of risk with a vastly superior positive predictive value for CRC, while conversely identifying a truly low risk cohort of patients. The aim of this guideline was to provide a clear strategy for the use of FIT in the diagnostic pathway of people with signs or symptoms of a suspected diagnosis of CRC. The guideline was jointly developed by the Association of Coloproctology of Great Britain and Ireland/British Society of Gastroenterology, specifically by a 21-member multidisciplinary guideline development group (GDG). A systematic review of 13 535 publications was undertaken to develop 23 evidence and expert opinion-based recommendations for the triage of people with symptoms of a suspected CRC diagnosis in primary care. In order to achieve consensus among a broad group of key stakeholders, we completed an extended Delphi of the GDG, and also 61 other individuals across the UK and Ireland, including by members of the public, charities and primary and secondary care. Seventeen research recommendations were also prioritised to inform clinical management.
Assessing Digital Mental Health Apps: The Importance of Patient-Centric Measures of Utility
Stroud, Austin M. , Richardson, Jordan , Sharp, Richard R , Richardson, Jordan P , Sharp, Richard R.

Mayo Clinic

AJOB Neuroscience | July 7, 2022 | Volume: 13 | Issue: 3 | Pages: 209-211

10.1080/21507740.2022.2082591 | PMID 35797116 Get It

Enhancing the Trustworthiness of the Endocrine Society’s Clinical Practice Guidelines
McCartney, Christopher R. , Corrigan, Maureen D. , Drake, Matthew T. , Fuleihan, Ghada El‐Hajj , Korytkowski, Mary T. , Lash, Robert W. , Lieb, David C. , McCall, Anthony L. , Muniyappa, Ranganath , Piggott, Thomas , Schünemann, Holger J. , El-Hajj Fuleihan, Ghada , Schünemann, Holger J , Wiercioch, Wojtek , McDonnell, Marie E , Murad, M Hassan , Drake, Matthew T , Muniyappa, Ranganath , McCartney, Christopher R , Piggott, Thomas , Santesso, Nancy A. , Wiercioch, Wojtek , McDonnell, Marie E. , Murad, M. Hassan

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 12, 2022 | Volume: 107 | Issue: 8 | Pages: 2129-2138

10.1210/clinem/dgac290 | PMID 35690966 Get It

Abstract In an effort to enhance the trustworthiness of its clinical practice guidelines, the Endocrine Society has recently adopted new policies and more rigorous methodologies for its guideline program. In this Clinical Practice Guideline Communication, we describe these recent enhancements—many of which reflect greater adherence to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to guideline development—in addition to the rationale for such changes. Improvements to the Society’s guideline development practices include, but are not limited to, enhanced inclusion of nonendocrinologist experts, including patient representatives, on guideline development panels; implementation of a more rigorous conflict/duality of interest policy; a requirement that all formal recommendations must be demonstrably underpinned by systematic evidence review; the explicit use of GRADE Evidence-to-Decision frameworks; greater use and explanation of standardized guideline language; and a more intentional approach to guideline updating. Lastly, we describe some of the experiential differences our guideline readers are most likely to notice.
Assessing socioeconomic bias in machine learning algorithms in health care: a case study of the HOUSES index
Juhn, Young J. , Ryu, Euijung , King, Katherine S. , Malik, Momin M. , Romero‐Brufau, Santiago , Sohn, Sunghwan , Sharp, Richard R. , Halamka, John , King, Katherine , Malik, Momin , Romero-Brufau, Santiago , Halamka, John D , Sharp, Richard R , Wi, Chung‐Il , Weng, Chunhua

Mayo Clinic

Journal of the American Medical Informatics Association | April 9, 2022 | Volume: 29 | Issue: 7 | Pages: 1142-1151

10.1093/jamia/ocac052 | PMID 35396996 Get It

Abstract Objective Artificial intelligence (AI) models may propagate harmful biases in performance and hence negatively affect the underserved. We aimed to assess the degree to which data quality of electronic health records (EHRs) affected by inequities related to low socioeconomic status (SES), results in differential performance of AI models across SES. Materials and Methods This study utilized existing machine learning models for predicting asthma exacerbation in children with asthma. We compared balanced error rate (BER) against different SES levels measured by HOUsing-based SocioEconomic Status measure (HOUSES) index. As a possible mechanism for differential performance, we also compared incompleteness of EHR information relevant to asthma care by SES. Results Asthmatic children with lower SES had larger BER than those with higher SES (eg, ratio = 1.35 for HOUSES Q1 vs Q2–Q4) and had a higher proportion of missing information relevant to asthma care (eg, 41% vs 24% for missing asthma severity and 12% vs 9.8% for undiagnosed asthma despite meeting asthma criteria). Discussion Our study suggests that lower SES is associated with worse predictive model performance. It also highlights the potential role of incomplete EHR data in this differential performance and suggests a way to mitigate this bias. Conclusion The HOUSES index allows AI researchers to assess bias in predictive model performance by SES. Although our case study was based on a small sample size and a single-site study, the study results highlight a potential strategy for identifying bias by using an innovative SES measure.
A framework for examining patient attitudes regarding applications of artificial intelligence in healthcare
Richardson, Jordan , Smith, Cambray , Barry, Barbara , Sharp, Richard R. , Richardson, Jordan P , Curtis, Susan , Pacyna, Joel, Zhu, Xuan , Barry, Barbara , Sharp, Richard R , Pacyna, Joel E.

Mayo Clinic

DIGITAL HEALTH | March 25, 2022 | Volume: 8 | Issue: No issue available | Pages: 205520762210890

10.1177/20552076221089084 | PMID 35355806 Get It

Background While use of artificial intelligence (AI) in healthcare is increasing, little is known about how patients view healthcare AI. Characterizing patient attitudes and beliefs about healthcare AI and the factors that lead to these attitudes can help ensure patient values are in close alignment with the implementation of these new technologies. Methods We conducted 15 focus groups with adult patients who had a recent primary care visit at a large academic health center. Using modified grounded theory, focus-group data was analyzed for themes related to the formation of attitudes and beliefs about healthcare AI. Results When evaluating AI in healthcare, we found that patients draw on a variety of factors to contextualize these new technologies including previous experiences of illness, interactions with health systems and established health technologies, comfort with other information technology, and other personal experiences. We found that these experiences informed normative and cultural beliefs about the values and goals of healthcare technologies that patients applied when engaging with AI. The results of this study form the basis for a theoretical framework for understanding patient orientation to applications of AI in healthcare, highlighting a number of specific social, health, and technological experiences that will likely shape patient opinions about future healthcare AI applications. Conclusions Understanding the basis of patient attitudes and beliefs about healthcare AI is a crucial first step in effective patient engagement and education. The theoretical framework we present provides a foundation for future studies examining patient opinions about applications of AI in healthcare.
Ergonomic education in dermatology training: A survey
Deo, Neha , Carley, Sama K. , Mullen, Barbara , Vidal, Nahid Y. , Deo, Neha N

Mayo Clinic

Australasian Journal of Dermatology | January 31, 2022 | Volume: 63 | Issue: 2 | Pages: No page available

10.1111/ajd.13788 | PMID 35099069 Get It

Visuospatial impairment in logopenic progressive aphasia: Why do we not “see” it?
Pudumjee, Shehroo B. , Martin, Peter R. , Bailey, Kimberly, Caves, Courtney, Sharp, Blair, Graff‐Radford, Jonathan , Josephs, Keith A. , Whitwell, Jennifer L. , Duffy, Joseph R. , Clark, Heather M. , Botha, Hugo , Machulda, Mary M.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S6 | Pages: No page available

10.1002/alz.055810 Get It

AbstractBackgroundLogopenic progressive aphasia (LPA) and posterior cortical atrophy (PCA) have distinct patterns of hypometabolism and atrophy. However, these clinical syndromes overlap: visuospatial impairment has been documented in LPA and aphasia in PCA. Rey‐Osterrieth Complex Figure – Copy (Rey‐O Copy) performance is correlated with parietal‐occipital atrophy in LPA. We explore visuospatial impairment on the Rey‐O Copy in LPA and PCA with the Mayo Older Americans Normative Studies (MOANS; which uses Meyers & Meyers criteria) and the Boston Qualitative Scoring System (BQSS). We also examine the proportion of visuospatial impairment in LPA, an under‐appreciated phenomenon, compared to PCA wherein it is fundamental.MethodPatients with LPA (n=25) or PCA (n=23) were recruited by the Neurodegenerative Research Group. Patients underwent comprehensive neuropsychological testing (including Rey‐O Copy) at baseline visit. Cut‐offs of T‐score=40 (BQSS) or scaled score=7 (MOANS) were used based on normative data. Proportions of patients with low performance were examined across LPA and PCA groups. Individual logistic regressions and AUROC analyses were then conducted to quantify differences in visuospatial impairment in LPA and PCA with both scoring systems. Identical analyses were conducted using raw scores corrected for age and sex, to avoid confounds of adjustments in normative data.ResultLPA and PCA groups were comparable on age, sex, and disease duration (LPA Median = 2.7 years, IQR=1.9‐3.5; PCA Median = 3.6 years, IQR=1.5‐4.9); p=.823). Surprisingly, 52‐72% of LPA participants demonstrated impaired performance across scoring systems, relative to 96% of the PCA group identified by both scoring systems. Odds ratios (OR) for the Rey‐O Copy MOANS (OR = 1.59; p=.008) and BQSS Copy Presence and Accuracy index (CPA; OR = 1.13, p=.002) were significant, persisting for age‐ and sex‐ controlled raw scores, suggesting the odds of a PCA diagnosis increased with decrement on Rey‐O Copy. AUROC values ranged from 0.77 to 0.88 across these indices.ConclusionA substantial number of LPA participants showed visuospatial impairment, despite initial primary language complaints. Differentiation of diagnostic groups by the Rey‐O is likely underscored by relatively uniform, profound, visuospatial impairment in PCA with more variability in LPA. However, the degree of visuospatial impairment overlaps remarkably across diagnoses.
The Need for “Big Bioethics” Research
Pacyna, Joel E. , Sharp, Richard R. , Sharp, Richard R

Mayo Clinic

The American Journal of Bioethics | December 28, 2021 | Volume: 22 | Issue: 1 | Pages: 3-5

10.1080/15265161.2022.2009701 | PMID 34962190 Get It

Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words?
Meagher, Karen M. , Finn, Kelsey Stuttgen , Curtis, Susan , Borucki, Jack, Beck, Annika T., Cheema, Amal , Sharp, Richard R. , Stuttgen Finn, Kelsey, Curtis, Susan H , Cheema, Amal W, Sharp, Richard R , Meagher, Karen M , Stuttgen, Kelsey

Mayo Clinic

Clinical and Translational Science | November 10, 2021 | Volume: 15 | Issue: 3 | Pages: 721-731

10.1111/cts.13193 | PMID 34755460 Get It

AbstractAs pharmacogenomic (PGx) testing increases in popularity, lay concepts of drug‐gene interactions set the stage for shared decision making in precision medicine. Few studies explore what recipients of PGx results think is happening in their bodies when a drug‐gene interaction is discovered. To characterize biobank participants’ understanding of PGx research results, we conducted a focus group study, which took place after PGx variants conferring increased risk of dihydropyrimidine dehydrogenase (DPD) deficiency were disclosed to biobank contributors. DPD deficiency confers an increased risk of adverse reaction to commonly used cancer chemotherapeutics. Ten focus groups were conducted, ranging from two to eight participants. Fifty‐four individuals participated in focus groups. A framework approach was used for descriptive and explanatory analysis. Descriptive themes included participants’ efforts to make sense of PGx findings as they related to: (1) health implications, (2) drugs, and (3) genetics. Explanatory analysis supplied a functional framework of how participant word choices can perform different purposes in PGx communication. Results bear three main implications for PGx research‐related disclosure. First, participants’ use of various terms suggest participants generally understanding their PGx results, including how positive PGx results differ from positive disease susceptibility genetic results. Second, PGx disclosure in biobanking can involve participant conflation of drug‐gene interactions with allergies or other types of medical reactions. Third, the functional framework suggests a need to move beyond a deficit model of genetic literacy in PGx communication. Together, findings provide an initial evidence base for supporting bidirectional expert‐recipient PGx results communication.